[1]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮治疗小鼠非酒精性脂肪性肝病效果及机制研究[J].陕西医学杂志,2023,52(9):1135-1139,1144.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.005]
　ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Effect and mechanism of cryptotanshinone on nonalcoholic fatty liver disease in mice[J].,2023,52(9):1135-1139,1144.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.005]
点击复制

隐丹参酮治疗小鼠非酒精性脂肪性肝病效果及机制研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年9期
页码:
1135-1139,1144
栏目:
基础研究
出版日期:
2023-09-05

文章信息/Info

Title:
Effect and mechanism of cryptotanshinone on nonalcoholic fatty liver disease in mice
作者:
赵梦溪; 罗 斌; 吕建瑞; 王 宁
(西安交通大学第二附属医院,陕西 西安 710004)
Author(s):
ZHAO Mengxi; LUO Bin; LYU Jianrui; WANG Ning
(The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China)
关键词:
非酒精性脂肪性肝病;  隐丹参酮;  脂肪酸β-氧化;  脂质代谢;  氧化应激;  炎症反应
Keywords:
Nonalcoholic fatty liver disease;  Cryptotanshinone;  Fatty acid β-oxidation;  Lipid metabolism;  Oxidative stress;  Inflammatory response
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7377.2023.09.005
文献标志码:
A
摘要:
目的:探讨隐丹参酮对小鼠非酒精性脂肪性肝病的治疗效果及相关机制。方法:将雄性C57BL/6J小鼠随机分为正常组、模型组以及隐丹参酮低、中和高剂量组,每组10只。造模8周干预4周后,采集小鼠血液检测谷丙转氨酶(ALT)和谷草转氨酶(AST); 行组织病理学染色观察小鼠肝脏组织; 检测肝脏组织总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽(GSH)、肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)和IL-6等指标。Western blot法检测肉碱棕榈酰转移酶1(CPT1)、酰基辅酶A氧化酶1(ACOX1)以及过氧化物酶体增殖物激活受体α(PPARα)蛋白表达水平。结果:肝脏组织病理染色结果显示,正常组几乎无脂肪浸润,模型组小鼠肝脏组织存在大量脂肪空泡,隐丹参酮低、中和高剂量组较模型组肝脏组织病变明显改善。与正常组比较,模型组AST、ALT、TC、TG、LDL-C、TNF-α、IL-1β、IL-6、MDA 水平升高,HDL-C、SOD、GSH水平降低(均P<0.05)。与模型组比较,隐丹参酮低、中和高剂量组ALT、AST、TC、TG、LDL-C、TNF-α、IL-1β、IL-6、MDA 水平降低,HDL-C、SOD、GSH 水平升高(均P<0.05)。与正常组比较,模型组PPARα、CPT1和ACOX1蛋白表达水平降低(均P<0.05)。与模型组比较,隐丹参酮低、中和高剂量组PPARα、CPT1和ACOX1蛋白表达水平升高(均P<0.05)。结论:隐丹参酮对NAFLD具有治疗作用,能够改善脂质代谢,促进肝脏脂质排出,改善肝功能和减少肝脏脂质沉积,其机制可能与调节脂肪酸β-氧化、减轻炎症反应及平衡氧化应激有关。
Abstract:
Objective:To investigate the therapeutic effect of cryptotanshinone on nonalcoholic fatty liver disease in mice and its mechanism.Methods:The C57BL/6J mice(males)were divided randomly into normal group,model group and cryptotanshinone low-,medium- and high-dose group,10 mice in each group.After 8 weeks of modeling and 4 weeks of intervention,blood samples were collected to detect ALT and AST.Their liver was collected for liver histopathology.Meanwhile,TC,TG,HDL-C,LDL-C,MDA,GSH,SOD,TNF-α,IL-1β and IL-6 in the liver were detected.Finally,Western blot was used to detected the expression characteristics of peroxisome proliferator-activated receptor α(PPARα),carnitine palmitoyl transferase 1(CPT1)and acyl CoA oxidase 1(ACOX1).Results:The results of pathological staining of liver tissue showed that there was almost no fatty infiltration in normal group,and there were a lot of fatty vacuoles in the liver tissue of model group; compared with model group,the cryptotanshinone low-,medium- and high-dose groups had significantly improved liver tissue lesions.Compared with normal group,the levels of AST,ALT,TC,TG,LDL-C,TNF-α,IL-1β,IL-6 and MDA were increased,and the levels of HDL-C,SOD and GSH were decreased in model group(all P<0.05).Compared with model group,the levels of ALT,AST,TC,TG,LDL-C,TNF-α,IL-1β,IL-6 and MDA were decreased,and the levels of HDL-C,SOD and GSH were increased in cryptotanshinone low-,medium- and high-dose groups(all P<0.05).Compared with normal group,the protein expression levels of PPARα,CPT1 and ACOX1 in model group were decreased(all P<0.05).Compared with model group,the protein expression levels of PPARα,CPT1 and ACOX1 were increased in cryptotanshinone low-,medium- and high-dose groups(all P<0.05).Conclusion:Cryptotanshinone has therapeutic effects on NAFLD,which can improve lipid metabolism,promote liver lipid excretion,improve liver function and reduce liver lipid deposition.The mechanism may be related to regulating fatty acid β-oxidation,reducing inflammatory response and balancing oxidative stress.

参考文献/References:

[1] Nassir F.NAFLD:Mechanisms,treatments,and biomarkers[J].Biomolecules,2022,12(6):824.
[2] 王智勇,宋 凯,郝祥蕊,等.细菌中脂肪酸β-氧化途径与机理的研究进展[J].激光生物学报,2021,30(6):494-504.
[3] 杨 婧.银杏内酯B调节长链脂肪酸β-氧化相关蛋白表达治疗非酒精性脂肪性肝病机制[D].昆明:云南中医药大学,2022.
[4] 周 杨.隐丹参酮对脂多糖诱导的BV2小胶质细胞炎症反应的影响及其机制研究[D].蚌埠:蚌埠医学院,2020.
[5] 谢 嵩,于宗琴,徐济萍.隐丹参酮对小鼠肝微粒体内阿司匹林酯酶活性的影响[J].中国医院药学杂志,2014,34(2):94-97.
[6] 秦 魏,邢 露,杨智慧,等.丹参活性成分在抗动脉粥样硬化中的作用与机制研究进展[J].陕西中医,2021,42(7):977-979.
[7] 刘新叶,李 勇,杨东伟.盾叶冠心宁联合丹参酮治疗冠状动脉粥样硬化疗效及对患者左室功能的影响[J].陕西中医,2019,40(5):584-586.
[8] Salvoza N,Giraudi PJ,Tiribelli C,et al.Natural compounds for counteracting nonalcoholic fatty liver disease(NAFLD):Advantages and limitations of the suggested candidates[J].Int J Mol Sci,2022,23(5):2764.
[9] Palma R,Pronio A,Romeo M,et al.The role of insulin resistance in fueling NAFLD pathogenesis:From molecular mechanisms to clinical implications[J].J Clin Med,2022,11(13):3649.
[10] Targher G,Byrne CD,Tilg H.NAFLD and increased risk of cardiovascular disease:Clinical associations,pathophysiological mechanisms and pharmacological implications[J].Gut,2020,69(9):1691-1705.
[11] Colak Y,Hasan B,Erkalma B,et al.Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target[J].Clin Res Hepatol Gastroenterol,2021,45(4):101710.
[12] Zhou J,Bai L,Zhang XJ,et al.Nonalcoholic fatty liver disease and cardiac remodeling risk:Pathophysiological mechanisms and clinical implications[J].Hepatology,2021,74(5):2839-2847.
[13] 陈 妍,缪 娟,高 宏.欧芹根对非酒精性脂肪肝大鼠的有效成分及机制研究[J].陕西医学杂志,2016,45(9):1112-1113.
[14] Wang K,Tan W,Liu X,et al.New insight and potential therapy for NAFLD:CYP2E1 and flavonoids[J].Biomed Pharmacother,2021,137:111326.
[15] Chen K,Ma J,Jia X,et al.Advancing the understanding of NAFLD to hepatocellular carcinoma development:From experimental models to humans[J].Biochim Biophys Acta Rev Cancer,2019,1871(1):117-125.
[16] Murase T,Aoki M,Tokimitsu I.Supplementation with alpha-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of beta-oxidation in zucker fatty rats[J].Biochim Biophys Acta,2005,1733(2-3):224-231.
[17] 田 香.梓醇对非酒精性脂肪肝病的预防作用及其机制研究[D].武汉:湖北大学,2020.
[18] 廖文云,徐 丹.人参皂苷Rg1对非酒精性脂肪肝病大鼠脂肪酸β-氧化的改善作用研究[J].重庆医学,2016,45(9):1179-1182.
[19] 喻春辉,李 双,江振峰,等.丹参酮ⅡA调节肝脏HNF1α-Fxr信号通路抑制小鼠非酒精性脂肪肝进程[J].江西医药,2022,57(3):239-242.
[20] 路 帅,韩 雪,张睦清,等.丹参防治大鼠非酒精性脂肪肝的药效机制研究[J].甘肃中医学院学报,2012,29(2):4-6.
[21] 卢向琴.丹参治疗非酒精性脂肪肝的荟萃分析[J].海峡药学,2013,25(5):83-84.
[22] Zeng S,Wu F,Chen M,et al.Inhibition of fatty acid translocase(FAT/CD36)palmitoylation enhances hepatic fatty acid β-oxidation by increasing its localization to mitochondria and interaction with long-chain acyl-CoA synthetase 1[J].Antioxid Redox Signal,2022,36(16-18):1081-1100.
[23] 郑文博,赵 瑛.冬凌草甲素对高脂饮食诱导幼龄大鼠非酒精性脂肪肝的作用及相关机制[J].陕西医学杂志,2021,50(12):1496-1500.

相似文献/References:

[1]刘 颖,李远辙,周声毅,等.脉冲电磁场调控SREBP1c及氧化应激改善db/db小鼠肝脂肪变性研究*[J].陕西医学杂志,2019,(9):1107.
　LIU Ying,LI Yuanzhe,ZHOU Shengyi,et al.Pulsed electromagnetic fields improves hepatic steatosis 〖JZ〗in db/db mice by SREBP1c and oxidative stress[J].,2019,(9):1107.
[2]刘玲娇,余湘尤,虢小丽.西安市职业人群非酒精性脂肪性肝病患病率及其危险因素调查研究[J].陕西医学杂志,2021,50(1):107.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.029]
　LIU Lingjiao,YU Xiangyou,GUO Xiaoli.Prevalence and risk factors of nonalcoholic fatty liver disease among occupational population in Xi'an[J].,2021,50(9):107.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.029]
[3]李 婧,李小凤,闫 妮,等.胰岛素抵抗代谢评分在中老年人群非酒精性脂肪性肝病筛查中的价值研究[J].陕西医学杂志,2023,52(6):688.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.011]
　LI Jing,LI Xiaofeng,YAN Ni,et al.Value of metabolic score for insulin resistance in screening non-alcoholic fatty liver disease in middle-aged and elderly people[J].,2023,52(9):688.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.011]
[4]梁 娜,张泽天,孙晓冉,等.低密度脂蛋白相关受体蛋白6基因多态性与非酒精性脂肪性肝病发病关系研究[J].陕西医学杂志,2023,52(9):1241.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.030]
　LIANG Na,ZHANG Zetian,SUN Xiaoran,et al.Relationship between low-density lipoprotein receptor-related protein 6 gene polymorphism and occurrence of nonalcoholic fatty liver disease[J].,2023,52(9):1241.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.030]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2022SF-038)
更新日期/Last Update: 2023-09-04